140 related articles for article (PubMed ID: 31961035)
1. Eradication of factor IX neutralizing and anaphylactic inhibitors in a patient with severe haemophilia B using cyclophosphamide immune suppression and factor IX desensitization.
Greenmyer JR; Grindeland CJ; Kobrinsky NL
Haemophilia; 2020 Mar; 26(2):e51-e54. PubMed ID: 31961035
[No Abstract] [Full Text] [Related]
2. Induction of immune tolerance using rituximab in a child with severe haemophilia B with inhibitors and anaphylaxis to factor IX.
Barnes C; Davis A; Furmedge J; Egan B; Donnan L; Monagle P
Haemophilia; 2010 Sep; 16(5):840-1. PubMed ID: 20546030
[No Abstract] [Full Text] [Related]
3. The use of rituximab as an adjuvant for immune tolerance therapy in a hemophilia B boy with inhibitor and anaphylaxis to factor IX concentrate.
Chuansumrit A; Moonsup Y; Sirachainan N; Benjaponpitak S; Suebsangad A; Wongwerawattanakoon P
Blood Coagul Fibrinolysis; 2008 Apr; 19(3):208-11. PubMed ID: 18388500
[TBL] [Abstract][Full Text] [Related]
4. Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner U
Thromb Haemost; 1999 Aug; 82(2):531-9. PubMed ID: 10605747
[No Abstract] [Full Text] [Related]
5. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). UK Haemophilia Centre Doctors Organization.
Collins PW; Chalmers E; Hart DP; Liesner R; Rangarajan S; Talks K; Williams M; Hay CR;
Br J Haematol; 2013 Jan; 160(2):153-70. PubMed ID: 23157203
[No Abstract] [Full Text] [Related]
6. Successful multi-modal immune tolerance induction for factor IX deficiency with inhibitors and allergic reactions.
Kuhn J; Noda C; Massey GV
Haemophilia; 2018 May; 24(3):e133-e136. PubMed ID: 29600592
[No Abstract] [Full Text] [Related]
7. Failure of immunosuppression in a severe haemophilia B patient with specific antibody.
Allain JP; Frommel D
Thromb Haemost; 1976 Aug; 36(1):86-9. PubMed ID: 1036830
[TBL] [Abstract][Full Text] [Related]
8. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Gamerman S; Singh AM; Makhija M; Sharathkumar A
Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
[No Abstract] [Full Text] [Related]
9. Rituximab and desensitization for a patient with severe factor IX deficiency, inhibitors, and history of anaphylaxis.
Alexander S; Hopewell S; Hunter S; Chouksey A
J Pediatr Hematol Oncol; 2008 Jan; 30(1):93-5. PubMed ID: 18176193
[TBL] [Abstract][Full Text] [Related]
10. Key issues in inhibitor management in patients with haemophilia.
Gomez K; Klamroth R; Mahlangu J; Mancuso ME; Mingot ME; Ozelo MC
Blood Transfus; 2014 Jan; 12 Suppl 1(Suppl 1):s319-29. PubMed ID: 24333092
[No Abstract] [Full Text] [Related]
11. Management of haemophilia B patients with inhibitors and anaphylaxis.
Warrier I
Haemophilia; 1998 Jul; 4(4):574-6. PubMed ID: 9873797
[TBL] [Abstract][Full Text] [Related]
12. A therapeutic alternative for haemophiliacs with inhibitors.
Schulman S
Acta Paediatr; 1992; 81(6-7):564-5. PubMed ID: 1392376
[No Abstract] [Full Text] [Related]
13. Anaphylactoid reactions and nephrotic syndrome--a considerable risk during factor IX treatment in patients with haemophilia B and inhibitors: a report on the outcome in two brothers.
Tengborn L; Hansson S; Fasth A; Lübeck PO; Berg A; Ljung R
Haemophilia; 1998 Nov; 4(6):854-9. PubMed ID: 10028310
[TBL] [Abstract][Full Text] [Related]
14. Immunosuppressive agents in the treatment of inhibitors in congenital haemophilia A and B--a systematic literature review.
Laros-van Gorkom BA; Falaise C; Astermark J
Eur J Haematol Suppl; 2014 Aug; 76():26-38. PubMed ID: 24957105
[TBL] [Abstract][Full Text] [Related]
15. Desensitization and immune tolerance induction in children with severe factor IX deficiency; inhibitors and adverse reactions to replacement therapy: a case-report and literature review.
Bon A; Morfini M; Dini A; Mori F; Barni S; Gianluca S; de Martino M; Novembre E
Ital J Pediatr; 2015 Feb; 41():12. PubMed ID: 25887512
[TBL] [Abstract][Full Text] [Related]
16. Continuous infusion of factor IX concentrate to induce immune tolerance in two patients with haemophilia B.
Tengborn L; Berntorp E
Haemophilia; 1998 Jan; 4(1):56-9. PubMed ID: 9873867
[TBL] [Abstract][Full Text] [Related]
17. IgE-mediated allergy and desensitization to factor IX in hemophilia B.
Dioun AF; Ewenstein BM; Geha RS; Schneider LC
J Allergy Clin Immunol; 1998 Jul; 102(1):113-7. PubMed ID: 9679854
[TBL] [Abstract][Full Text] [Related]
18. Successful second ITI with factor IX and combined immunosuppressive therapy. A patient with severe haemophilia B and recurrence of a factor IX inhibitor.
Holstein K; Schneppenheim R; Schrum J; Bokemeyer C; Langer F
Hamostaseologie; 2014; 34 Suppl 1():S5-8. PubMed ID: 25382771
[TBL] [Abstract][Full Text] [Related]
19. Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency.
Scharrer I
Haemophilia; 1999 Jul; 5(4):253-9. PubMed ID: 10469179
[TBL] [Abstract][Full Text] [Related]
20. Prolonged recombinant activated factor VII (rFVIIa) treatment for severe bleeding in a factor-IX-deficient patient with an inhibitor.
Schmidt ML; Smith HE; Gamerman S; DiMichele D; Glazer S; Scott JP
Br J Haematol; 1991 Jul; 78(3):460-3. PubMed ID: 1873233
[No Abstract] [Full Text] [Related]
[Next] [New Search]
